F Vermeer

Summary

Affiliation: University Hospital Maastricht
Country: The Netherlands

Publications

  1. ncbi request reprint Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study
    F Vermeer
    University of Maastricht, Maastricht, The Netherlands
    J Thromb Thrombolysis 8:143-50. 1999
  2. pmc Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study
    F Vermeer
    University Hospital Maastricht, Department of Cardiology, PO Box 5800, 6202 AZ, Maastricht, Netherlands
    Heart 82:426-31. 1999
  3. ncbi request reprint Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study
    F Vermeer
    Department of Cardiology, University Hospital, Maastricht, The Netherlands
    J Thromb Thrombolysis 10:233-40. 2000
  4. pmc Angiographic assessment of prospectively determined non-invasive reperfusion indices in acute myocardial infarction
    A J Ophuis
    Department of Cardiology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands
    Heart 84:164-70. 2000
  5. ncbi request reprint Thrombolytic therapy in patients of female gender
    F Vermeer
    University Hospital Maastricht, PO Box 5800, 6202 AZ, Maastricht, Netherlands
    Thromb Res 103:S101-4. 2001
  6. ncbi request reprint Cumulative enzyme release as a measure of infarct size in patients with acute myocardial infarction receiving thrombolytic therapy
    F Vermeer
    Department of Cardiology, University Hospital Maastricht, The Netherlands
    Arch Mal Coeur Vaiss 86:25-8. 1993
  7. pmc Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin
    B S Hellemons
    Department of General Practice, University of Maastricht, 6200 MD Maastricht, Netherlands
    BMJ 319:958-64. 1999
  8. ncbi request reprint [Treatment of patients with acute coronary syndromes in the Netherlands in 2000-2001; a comparison with other European countries and with the guidelines]
    R Nieuwlaat
    Academisch Ziekenhuis, afd Cardiologie, Postbus 5800, 6202 AZ Maastricht
    Ned Tijdschr Geneeskd 148:1878-82. 2004

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study
    F Vermeer
    University of Maastricht, Maastricht, The Netherlands
    J Thromb Thrombolysis 8:143-50. 1999
    ..In conclusion, it can be stated that saruplase, given in combination with aspirin and intravenous heparin, can be given safely and effectively to patients with acute myocardial infarction...
  2. pmc Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study
    F Vermeer
    University Hospital Maastricht, Department of Cardiology, PO Box 5800, 6202 AZ, Maastricht, Netherlands
    Heart 82:426-31. 1999
    ....
  3. ncbi request reprint Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study
    F Vermeer
    Department of Cardiology, University Hospital, Maastricht, The Netherlands
    J Thromb Thrombolysis 10:233-40. 2000
    ..Safety and efficacy of the combination alteplase and argatroban (with this dose regimen) are similar to those of alteplase and heparin...
  4. pmc Angiographic assessment of prospectively determined non-invasive reperfusion indices in acute myocardial infarction
    A J Ophuis
    Department of Cardiology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands
    Heart 84:164-70. 2000
    ..To investigate the value of non-invasive reperfusion indices in acute myocardial infarction, avoiding the possible need for acute coronary angiography and subsequent angioplasty...
  5. ncbi request reprint Thrombolytic therapy in patients of female gender
    F Vermeer
    University Hospital Maastricht, PO Box 5800, 6202 AZ, Maastricht, Netherlands
    Thromb Res 103:S101-4. 2001
    ..With the data presently available it can be stated that female patients and patients over 75 years of age will probably benefit more from a thrombolytic agent that is given according to a weight-adjusted dose regimen, e.g., tenecteplase...
  6. ncbi request reprint Cumulative enzyme release as a measure of infarct size in patients with acute myocardial infarction receiving thrombolytic therapy
    F Vermeer
    Department of Cardiology, University Hospital Maastricht, The Netherlands
    Arch Mal Coeur Vaiss 86:25-8. 1993
    ....
  7. pmc Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin
    B S Hellemons
    Department of General Practice, University of Maastricht, 6200 MD Maastricht, Netherlands
    BMJ 319:958-64. 1999
    ..To investigate the effectiveness of aspirin and coumarin in preventing thromboembolism in patients with non-rheumatic atrial fibrillation in general practice...
  8. ncbi request reprint [Treatment of patients with acute coronary syndromes in the Netherlands in 2000-2001; a comparison with other European countries and with the guidelines]
    R Nieuwlaat
    Academisch Ziekenhuis, afd Cardiologie, Postbus 5800, 6202 AZ Maastricht
    Ned Tijdschr Geneeskd 148:1878-82. 2004
    ....